Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Part two of this series sees Ravijyot Saggu explore pharmacological management recommendations from the new joint chronic ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

The ingredient in carmine causing these delayed hypersensitivity reactions has not been studied. In contrast, there are numerous reports of immediate hypersensitivity reactions from carmine ...

However, higher age was ... Feb. 3, 2025 — A multi-institutional study has identified one of the allergens responsible for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus.

Add videos to your saved list and come back to them any time.

Auto news: Mitsubishi to sit out Nissan and Honda merger. © 2025 Nine Entertainment Co.